The device, developed by Urologix, Inc., will be launched under the brand name TargisD4 system. The disease typically occurs in men over 50 and is characterized by troublesome symptoms that affect quality of life, such as the sudden urgency to urinate and increased frequency of urination. BPH is a non-cancerous disease caused by prostate cells that grow and compress the urethra, restricting the flow of urine. The prostate is a walnut-shaped gland that surrounds the male urethra.
Urologists are now able to destroy the diseased tissue while preserving healthy tissue.
This gives us an effective, durable treatment that can be delivered in an outpatient treatment room as truly anesthesia-free therapy. The one-hour Targis procedure is performed by a urologist who inserts a flexible treatment catheter into the urethra. A patented microwave antenna inside the catheter delivers precisely targeted microwave energy, which creates high temperatures and destroys the diseased prostate tissue. Simultaneously, the catheter also cools and protects the adjacent urethra and healthy tissue, thereby minimizing discomfort, complications and recovery time. M.D. Only a small number of Targis patients required retreatment within three years after receiving the therapy, Ramsay indicated at the recent meeting of the Canadian Urological Association.